Skip to content

Richard S. Finn

University of California, Los Angeles

3 papers in the Anchorcite directory, published between 2017 and 2020, cited 16,454 times in total.

ORCID profile

Research topics

Frequent co-authors

  • Andrew Xiuxuan Zhu · 3 papers
  • Jorge A. Marrero · 2 papers
  • Laura Kulik · 2 papers
  • Claude B. Sirlin · 2 papers
  • Michael M. Abecassis · 2 papers
  • Lewis Rowland Roberts · 2 papers
  • Julie K. Heimbach · 2 papers
  • Shukui Qin · 1 paper

Papers

  1. Atezolizumab plus Bevacizumab in Unresectable Hepatocellular CarcinomaNew England Journal of Medicine · 2020 · 7,704 citations

    BACKGROUND: The combination of atezolizumab and bevacizumab showed encouraging antitumor activity and safety in a phase 1b trial involving patients with unresectable hepatocellular carcinoma. METHODS: In a global, open-label, phase 3 trial, patients with unresectable hepatocellular carcinoma who had not…

  2. Diagnosis, Staging, and Management of Hepatocellular Carcinoma: 2018 Practice Guidance by the American Association for the Study of Liver DiseasesHepatology · 2018 · 4,629 citations

    Purpose and ScopeThis guidance provides a data-supported approach to the diagnosis, staging, and treatment of patients diagnosed with hepatocellular carcinoma (HCC).A guidance document is different from a guideline.Guidelines are developed by a multidisciplinary panel of experts who rate the quality…

  3. AASLD guidelines for the treatment of hepatocellular carcinomaHepatology · 2017 · 4,121 citations

    Potential conflict of interest: Laura M. Kulik is on the advisory board for Gilead, Bayer, Eisai, Salix, and Bristol‐Myers Squibb. Richard Finn consults for Pfizer, Bayer, Novartis, Merck, and Bristol‐Myers Squibb. Claude B. Sirlin consults for and has received grants…

Metadata from OpenAlex (CC0).